Taysha Gene Therapies Gross Margin 2020-2026 | TSHA

Current and historical gross margin for Taysha Gene Therapies (TSHA) over the last 10 years. The current gross profit margin for Taysha Gene Therapies as of March 31, 2026 is %.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Taysha Gene Therapies Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2025-12-31 $0.01B $0.01B 100.00%
2025-06-30 $0.01B $0.01B 100.00%
2025-03-31 $0.01B $0.01B 100.00%
2024-12-31 $0.01B $0.01B 100.00%
2024-09-30 $0.01B $0.01B 100.00%
2024-06-30 $0.01B $0.01B 100.00%
2024-03-31 $0.01B $0.01B 100.00%
2023-12-31 $0.02B $0.02B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.290B $0.010B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Metagenomi Therapeutics (MGX) United States $0.052B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00